RUMORED BUZZ ON HEMGENIX

Number of eligible sufferers: CDEC discussed the uncertainty in the quantity of patients with moderately significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some sufferers that are categorised as obtaining gentle or average disease could possibly have a critical b